HYUNDAI BIOSCIENCE CO., LTD. Logo

HYUNDAI BIOSCIENCE CO., LTD.

Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.

048410 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경상북도 김천시 아포읍 아포공단길 106, 김천시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

HYUNDAI BIOSCIENCE CO., LTD. is a clinical-stage biotechnology company focused on developing and commercializing innovative therapeutics through its advanced drug delivery systems (DDS) and bio-fusion technologies. The company's core mission is to create safer and more effective treatments for critical diseases. Its development pipeline features CP-COV03, a broad-spectrum antiviral drug candidate designed to treat viral infections by enhancing cellular autophagy, and Polytaxel, a next-generation anticancer agent engineered to minimize toxicity and patient discomfort. The company's proprietary technology platform, utilizing organic-inorganic hybrid materials, also underpins its commercialized bio-functional products. Through strategic partnerships with global universities and companies, Hyundai Bioscience aims to contribute significantly to human health and life extension.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 113.3 KB
2025-09-16 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 …
Korean 13.7 KB
2025-09-08 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
Korean 12.7 KB
2025-09-02 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청)
Korean 11.6 KB
2025-08-25 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-08-25 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.2 MB
2025-08-25 00:00
Interim Report
[기재정정]반기보고서 (2025.06)
Korean 1.2 MB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 118.2 KB
2025-08-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (췌장암 치료제 Polytaxel의 1상 임상시험계획 자진취하)
Korean 11.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-01 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.5 KB
2025-07-23 00:00
Share Issue/Capital Change
권리락 (무상증자)
Korean 3.5 KB
2025-07-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 116.0 KB
2025-07-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.